The efficacy and safety of 177Lu-DOTA-IBA in the treatment of bone metastases from lung cancer: a prospective single-arm study
|更新时间:2025-12-15
|
The efficacy and safety of 177Lu-DOTA-IBA in the treatment of bone metastases from lung cancer: a prospective single-arm study
“A study conducted by the Affiliated Hospital of Southwest Medical University shows that 177Lu DOTA-IBA has a significant therapeutic effect on lung cancer bone metastasis, with a pain relief rate of 82.2%, a physical improvement rate of 64.4%, and good safety.”
National Natural Science Foundation of China (NSFC)(82472016);Gansu Province Science and Technology Major Project(23ZDFA014);Isotope and Drug Innovation Fund of the National Engineering Research Center for Isotopes and Drugs(TWSCX-2023-CXJJ-3-1);Science and Technology Department of Sichuan Province(2024YFCY0005)
Xinyi LIN, Wei WANG, Tingting XU, et al. The efficacy and safety of 177Lu-DOTA-IBA in the treatment of bone metastases from lung cancer: a prospective single-arm study[J]. Oncoradiology, 2025, 34(5): 477-486.
DOI:
Xinyi LIN, Wei WANG, Tingting XU, et al. The efficacy and safety of 177Lu-DOTA-IBA in the treatment of bone metastases from lung cancer: a prospective single-arm study[J]. Oncoradiology, 2025, 34(5): 477-486. DOI: 10.19732/j.cnki.2096-6210.2025.05.006.
The efficacy and safety of 177Lu-DOTA-IBA in the treatment of bone metastases from lung cancer: a prospective single-arm study